Related posts

Crypto crumbles as stocks climbStocks, oil and cryptos rallyMarkets rally after Powell’s comments
BUY
Amgen Inc.
A big gainer in Q3

They bought a pharma company, luckily wasn't blocked by the FTC. Shares jumped 21% in Q3.

biotechnology / pharmaceutical
BUY
Amgen Inc.

His choice in the biotech space.

biotechnology / pharmaceutical
BUY
Amgen Inc.

He took some money out of tech and put it into healthcare, which has seen an increase lately. He just added Amgen who delieverd a terrific report. He will continue to rally in the second half this year, will outperform tech.

biotechnology / pharmaceutical
TOP PICK
Amgen Inc.

A long-term fine business and just reported good earnings. It's not in tech or industrials, so it has more stickiness. They made positive plans in their drug pipeline. Seasonally, now is the right time to buy biotech

(Analysts’ price target is $256.05)
biotechnology / pharmaceutical
BUY
Amgen Inc.

He bought it last week to diversify and get more exposure in pharmaceuticals. They report next week. Compare to Abbvie which just surprised with drug sales. There's some FT overhang, but shares have been bottoming out recently. If they announce good results, investors will chase this next week.

biotechnology / pharmaceutical
HOLD
Amgen Inc.

Facing a patent crisis as proprietary tech is challenged.
Shares have recently sold off.
Will take time to see how prospects play out.
Good hold, but other places to invest for new investors. 

biotechnology / pharmaceutical
TOP PICK
Amgen Inc.
Granddaddy of biotech. Even better than it used to be. Very deep bench of drugs. New acquisition will add growth on top of already-decent growth. Very strong financials. Income opportunity, stability, and some growth not yet fully priced in. Yield is 3.14%, well covered at 42%, increased by 11% average annually over 5 years. (Analysts’ price target is $268.80)
biotechnology / pharmaceutical
BUY
Amgen Inc.
Share have given up a lot since its Horizon Therapeutics deal, making it an opportunity.
biotechnology / pharmaceutical
BUY
Amgen Inc.
Today, they said they are buying Horizon Therapeutics for $27.8 billion. This deal should close quickly, since there's little overlap of these companies' drugs. Initially, he thought the price was high, but now he likes the deal. An established, big biotech that bought a younger biotech with exciting drugs at a 15% premium. Amgen wants HT's portfolio of drugs treating rare diseases and well-covered by insurance, therefore lucrative. HT's drugs will benefit from Amgen's worldwide distribution.
biotechnology / pharmaceutical
PAST TOP PICK
Amgen Inc.
(A Top Pick Nov 01/21, Up 20%) Bought it to be defensive for 2022. They announced a new facility in San Francisco. The future looks positive.
biotechnology / pharmaceutical
PAST TOP PICK
Amgen Inc.
(A Top Pick Nov 01/21, Up 20%) Bought it to be defensive for 2022. They announced a new facility in San Francisco. The future looks positive.
biotechnology / pharmaceutical
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
Amgen Inc.
(A Top Pick Nov 03/20, Up 4.1%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with AMGN has triggered its stop at $228. To remain disciplined, we recommend covering the holding at this time.
biotechnology / pharmaceutical
BUY
Amgen Inc.
Some of their key drugs are coming off patent, so he likes how they're making key buys of companies like CCXI, which would give Amgen exposure to drugs for auto-immune diseases and inflammatory conditions. CCXI has one drug on the market to treat blood vessel inflammation and a handful of phase 1 treatments including ulcerative colitis. The deal is good for Amgen.
biotechnology / pharmaceutical
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
Amgen Inc.
(A Top Pick Nov 03/20, Up 17.6%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with AMGN is progressing well. We now recommend trailing up the stop (from $218) to $228.
biotechnology / pharmaceutical
TOP PICK
Amgen Inc.
Are big worries about inflation and the economy and war. So, be in the US dollar, which should rally if the world goes deflationary. This is also a big name, and there's a massive rotation into the drug companies. He target $272. It pays a 3% dividend. (Analysts’ price target is $242.24)
biotechnology / pharmaceutical
Showing 1 to 15 of 123 entries

Amgen Inc.(AMGN-Q) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 6

Neutral - Hold Signals / Votes : 1

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 7

Stockchase rating for Amgen Inc. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Amgen Inc.(AMGN-Q) Frequently Asked Questions

What is Amgen Inc. stock symbol?

Amgen Inc. is a American stock, trading under the symbol AMGN-Q on the NASDAQ (AMGN). It is usually referred to as NASDAQ:AMGN or AMGN-Q

Is Amgen Inc. a buy or a sell?

In the last year, 7 stock analysts published opinions about AMGN-Q. 6 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Amgen Inc..

Is Amgen Inc. a good investment or a top pick?

Amgen Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Amgen Inc..

Why is Amgen Inc. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Amgen Inc. worth watching?

7 stock analysts on Stockchase covered Amgen Inc. In the last year. It is a trending stock that is worth watching.

What is Amgen Inc. stock price?

On 2023-12-01, Amgen Inc. (AMGN-Q) stock closed at a price of $272.45.